Having access to it will give our scientists opportunities to advance their research in ways that would be very hard for them to do in their own labs.” “The LGR screening center will enable labs at UCSF and Berkeley. “One of our key goals is to advance the field overall and make these tools as broadly available as possible,” Weissman said.
The ultimate goal is to deepen understanding of genetics and discover new targets, and to create next-generation technologies that will become future standard practice in the pharmaceutical industry. The LGR aims to automate and scale up existing CRISPR approaches. GSK’s artificial intelligence and machine learning group will also be involved in building the necessary computational pipelines to analyze all the data. With a focus on immunology, oncology and neuroscience, the laboratory will be based near the UCSF Mission Bay campus in San Francisco.
#SPEED DRUG PLUS#
The LGR will receive up to $67 million over a five-year period, which will include funds to build facilities for 24 full-time university employees plus up to 14 full-time GSK employees. I think we’re going to be able to do science that none of us can even imagine today.”
“LGR is about building that space where creative science is partnered with the development of robust technology that will help develop tomorrow’s drugs. “Over the last seven years, CRISPR has transformed academic research, but until the LGR, we haven’t had a focused effort to catalyze the kind of research we know will lead to new innovation using this CRISPR tool,” said Doudna.
In a video produced by GSK, Jennifer Doudna of Berkeley, Jonathan Weissman of UCSF and Hal Barron of GSK describe the goals of the new Laboratory for Genomics Research, which will be created in lab space adjacent to UCSF’s Mission Bay campus. The new laboratory will also be a resource for investigators at both UC campuses, who will be able to access and use its technology to answer their own biomedical or other biological questions, and to develop new tools that explore how genes work. The outputs of those research projects will be focused on technologies, new drug targets and biological mechanisms that will foster both academic and industrial advances. The LGR represents a novel hybrid model that brings together industrial and academic researchers under a single roof working on projects both together and independently. “With the expertise of Jennifer and Jonathan helping to steer the LGR, the mission of the lab is to advance our scientific understanding of the relationship between genes and disease to help find better medicines faster.” “Technology is key to our innovation strategy at GSK, and CRISPR is one of the most important technologies of our time,” Barron said. Through this research, scientists can discover and develop novel therapies that have a higher likelihood of becoming medicines. The most powerful tool in functional genomics, CRISPR, allows this to be done at a scale once thought impossible. With the recent explosion of information from human genetics, scientists need powerful tools to understand why small changes in a person’s genetic makeup can increase the risk of diseases, an area of science called functional genomics. The new Laboratory for Genomics Research (LGR) is the brainchild of Jennifer Doudna, a co-inventor of CRISPR technology, UC Berkeley professor of molecular and cell biology and of chemistry and Howard Hughes Medical Institute investigator Jonathan Weissman, a UCSF pioneer of CRISPR screening technology and an HHMI investigator and Hal Barron, the Chief Scientific Officer and President for R&D at GSK.
The pharmaceutical company GlaxoSmithKline ( GSK) today announced a five-year collaboration with UC Berkeley and UCSF to establish a laboratory where state-of-the-art CRISPR techniques will be used to explore how gene mutations cause disease, potentially yielding new technologies using CRISPR that would rapidly accelerate the discovery of new medicines. Jennifer Doudna and Jonathan Weissman are the key players in a new collaboration with GlaxoSmithKline to apply CRISPR techniques to the discovery of new drug targets, potentially leading to new therapies for genetic diseases. Berkeley Research Infrastructure Commons (RIC)
0 kommentar(er)
